BERRY GENOMICS(000710)
Search documents
AI医疗、AI制药概念震荡调整,泓博医药跌超18%
Mei Ri Jing Ji Xin Wen· 2026-01-15 02:17
Group 1 - The AI healthcare and AI pharmaceutical sectors experienced significant fluctuations, with notable declines in stock prices [1] - Hongbo Pharmaceutical saw a drop of over 18%, while Nossger fell nearly 15% [1] - Other companies such as International Medicine, Boji Pharmaceutical, Jiahe Meikang, and Berry Genomics also reported declines exceeding 5% [1]
贝瑞基因(000710) - 关于持股5%以上股东所持部分股份被司法强制执行实施结果的公告
2026-01-14 10:45
证券代码:000710 证券简称:贝瑞基因 公告编号:2026-001 成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东所持部分股份被司法强制执行实施结果的公告 | 股东名称 | 执行方式 | 执行期间 | 执行均价(元 /股) | 执行股数(万股) | | --- | --- | --- | --- | --- | | 高扬 | 集中竞价交易 | 2025年12月2日 2026年1月13日 | 11.92 | 353.5213 | 高扬先生被强制执行的股份来源于其在公司发行股份购买北京贝瑞和康生物技术 有限公司(以下简称"贝瑞和康")100%股权同时进行重大资产重组的交易中以持有 的贝瑞和康股权认购获得的新增股份。通过集中竞价强制执行股份的价格区间为11.66 元/股-14.45元/股。 | 2、本次强制执行前后持股情况 | | --- | 控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示: 成都市贝瑞和康基因技术股份有限公司(以下简称"公司"或"贝瑞基因")于 2025年1 ...
医疗服务板块开盘持续上扬,普蕊斯盘中涨超14%
Mei Ri Jing Ji Xin Wen· 2026-01-14 01:47
Group 1 - The healthcare services sector opened with a continuous upward trend, with Puris rising over 14% and reaching a new high during the session [1] - Meiyuan Health achieved a four-day consecutive increase, while New Mileage recorded a two-day consecutive increase [1] - International Medicine hit the daily limit, and companies such as Boteng Co., Zhaoyan New Drug, Nossger, Lanwei Medicine, and Berry Genomics also experienced gains [1]
医疗服务板块开盘持续上扬





Xin Lang Cai Jing· 2026-01-14 01:43
Core Viewpoint - The healthcare sector has shown a strong upward trend in opening trading, with several companies experiencing significant gains and reaching new highs [1] Group 1: Company Performance - Puris has surged over 14% and reached an intraday high [1] - Meiyuan Health has achieved a four-day consecutive increase [1] - New Mileage has recorded a two-day consecutive increase [1] - International Medicine has hit the daily limit [1] - Boteng Co., Zhaoyan New Drug, Nossger, Lanwei Medical, and Berry Genomics have also seen upward movements [1]
医疗服务板块1月13日涨4.15%,诺思格领涨,主力资金净流入14.97亿元
Zheng Xing Xing Ye Ri Bao· 2026-01-13 09:00
Core Insights - The medical services sector experienced a significant increase of 4.15% on January 13, with Norska leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Group 1: Stock Performance - Norska (301333) closed at 76.48, up 20.01% with a trading volume of 55,200 shares and a transaction value of 397 million yuan [1] - Yingsi (301257) also saw a rise of 20.00%, closing at 72.24 with a trading volume of 22,900 shares [1] - Hongbo Pharmaceutical (301230) increased by 20.00%, closing at 56.64 with a trading volume of 57,200 shares [1] - Lanwei Medical (301060) rose by 19.96%, closing at 13.28 with a trading volume of 135,210 shares [1] - Boji Pharmaceutical (300404) increased by 19.96%, closing at 12.92 with a trading volume of 627,100 shares [1] - Dian Diagnostics (300244) saw an increase of 11.90%, closing at 29.16 with a trading volume of 1,516,000 shares [1] Group 2: Capital Flow - The medical services sector saw a net inflow of 1.497 billion yuan from institutional investors, while retail investors experienced a net outflow of 713 million yuan [2] - The main stocks with significant capital flow include International Medical (000516) with a net inflow of 259 million yuan from institutional investors [3] - Boji Pharmaceutical (300404) had a net inflow of 243 million yuan from institutional investors, but also saw a net outflow of 140 million yuan from retail investors [3]
168只股中线走稳 站上半年线





Zheng Quan Shi Bao Wang· 2026-01-13 03:29
Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the six-month moving average, with a change of -0.03% [1] - The total trading volume of A-shares today is 185.05 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 168 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Nearshore Protein (近岸蛋白) with a deviation rate of 19.69% and a price increase of 19.99% [1] - Erkang Pharmaceutical (尔康制药) with a deviation rate of 17.97% and a price increase of 19.14% [1] - Wanbang Pharmaceutical (万邦医药) with a deviation rate of 12.41% and a price increase of 12.85% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Bo Wen Technology (博闻科技) with a deviation rate just above the average [1] - Jilin Expressway (吉林高速) and Teda Investment (泰达股份) also show minor deviations [1] Additional Notable Stocks - Other stocks with notable performance include: - Deer Medical (鹿得医疗) with a price increase of 13.63% and a deviation rate of 11.86% [1] - Chuaning Biological (川宁生物) with a price increase of 12.84% and a deviation rate of 10.67% [1] - New Zhi Biological (新芝生物) with a price increase of 14.33% and a deviation rate of 10.66% [1]
贝瑞基因股价涨1.25%,永赢基金旗下1只基金位居十大流通股东,持有152.68万股浮盈赚取21.38万元
Xin Lang Cai Jing· 2025-12-31 03:21
Group 1 - Core viewpoint: Berry Genomics has seen a stock price increase of 1.25%, reaching 11.30 CNY per share, with a total market capitalization of 3.995 billion CNY as of the report date [1] - Company overview: Berry Genomics, established on April 14, 1997, specializes in gene testing and sales of related equipment and reagents, with its main revenue sources being reagent sales (45.74%), medical testing services (31.24%), basic research services (18.33%), equipment sales (3.48%), and others (1.20%) [1] Group 2 - Major shareholders: The top circulating shareholder of Berry Genomics includes a fund from Yongying Fund, with the Medical Device ETF (159883) newly entering the top ten shareholders in Q3, holding 1.5268 million shares, which is 0.46% of the circulating shares [2] - ETF performance: The Medical Device ETF (159883) has a total size of 4.73 billion CNY, with a year-to-date return of 1.32%, ranking 3982 out of 4189 in its category, and a one-year loss of 0.34%, ranking 4000 out of 4188 [2]
贝瑞基因:2025年第一次临时股东大会决议公告
Zheng Quan Ri Bao· 2025-12-26 13:35
(文章来源:证券日报) 证券日报网讯 12月26日,贝瑞基因发布公告称,公司2025年12月26日召开2025年第一次临时股东大 会,审议通过《关于修订〈公司章程〉的议案》等多项议案。 ...
贝瑞基因(000710) - 2025年第一次临时股东大会决议公告
2025-12-26 11:00
证券代码:000710 证券简称:贝瑞基因 公告编号:2025-067 成都市贝瑞和康基因技术股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 1、会议时间: (1)现场会议召开时间:2025年12月26日(星期五)14:30 (2)网络投票时间:其中,通过深圳证券交易所交易系统进行网络投票的具体 时间为2025年12月26日9:15-9:25,9:30-11:30,13:00-15:00; 通过深圳证券交易所互联网投票系统投票的具体时间为:2025年12月26日9:15 —15:00。 2、会议地点:北京市昌平区生命园路4号院5号楼公司6层会议室 3、会议召开方式: 本次股东大会采用现场表决与网络投票相结合的方式。成都市贝瑞和康基因技 术股份有限公司(以下简称"公司")通过深圳证券交易所交易系统和互联网投票 系统(http://wltp.cninfo.com.cn)向全体股东提供网络形式的投票平台,股东在 网络投票时间内通过上述系统行使表决权。公司股东可以选择现场投票、网络投票 中的一 ...
贝瑞基因(000710) - 北京市金杜律师事务所关于贝瑞基因2025年第一次临时股东大会之法律意见书
2025-12-26 11:00
之法律意见书 致:成都市贝瑞和康基因技术股份有限公司 北京市金杜律师事务所(以下简称本所)接受成都市贝瑞和康基因技术股份 有限公司(以下简称公司)委托,根据《中华人民共和国证券法》(以下简称《证 券法》)、《中华人民共和国公司法》(以下简称《公司法》)、中国证券监督 管理委员会《上市公司股东会规则》(以下简称《股东会规则》)等中华人民共 和国境内(以下简称中国境内,为本法律意见书之目的,不包括中国香港特别行 政区、中国澳门特别行政区和中国台湾省)现行有效的法律、行政法规、规章和 规范性文件和现行有效的公司章程有关规定,指派律师现场出席了公司于 2025 年 12 月 26 日召开的 2025 年第一次临时年度股东大会(以下简称本次股东大会), 并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书,本所律师审查了公司提供的以下文件,包括但不限于: 1. 经公司 2023 年年度股东大会审议通过的《成都市贝瑞和康基因技术股份 有限公司章程》(以下简称《公司章程》); 北京市金杜律师事务所 关于成都市贝瑞和康基因技术股份有限公司 2025 年第一次临时股东大会 2. 公司 2025 年 12 月 10 日 ...